Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
NASDAQ:URGN
Price:
13.21 USD
-4.14%
Market Closed
Updated:
May 17, 2024
Urogen Pharma Ltd
Selling, General & Administrative
|
Urogen Pharma Ltd
Selling, General & Administrative Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
ENTX
B
BONS
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Selling, General & Administrative
-$93.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Selling, General & Administrative
-$6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Selling, General & Administrative
-$29.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-11%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Selling, General & Administrative
-$31.2m
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Selling, General & Administrative
-$4.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Selling, General & Administrative
-₪13.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
See Also
What is Urogen Pharma Ltd's Selling, General & Administrative?
Selling, General & Administrative
-93.3m
USD
-93.3m
USD
Based on the financial report for Dec 31, 2023, Urogen Pharma Ltd's Selling, General & Administrative amounts to -93.3m USD.
What is Urogen Pharma Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-19%
-19%
Over the last year, the Selling, General & Administrative growth was -13%. The average annual Selling, General & Administrative growth rates for Urogen Pharma Ltd have been -1% over the past three years , -19% over the past five years .
You don't have any saved screeners yet
